Maxioms Pet

X

Maxioms by Catherine Arnold

  ( comments )
  9  /  17  

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings read more

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

  ( comments )
  9  /  13  

This is half the savings that Pfizer achieved with its recently announced program.

This is half the savings that Pfizer achieved with its recently announced program.

  ( comments )
  9  /  14  

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to read more

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.

  ( comments )
  13  /  12  

We just can't get there. Maybe they see something we don't see.

We just can't get there. Maybe they see something we don't see.

  ( comments )
  7  /  15  

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really read more

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.

Maxioms Web Pet